

Interested Parties should contact:
Keith Ryan kryan@geneousbiomedical.com
617 444 8780



INVESTMENT OPPORTUNITY

AUTISM

EEG DIAGNOSTIC

Autism Spectrum Disorders (ASD) are a group of neuro-developmental disorders characterized by distinct behavioral traits. The average age of diagnosis is 4.5 years and the diagnostic/behavioral testing require significant training and is time intensive.

There is no cure for ASDs. However there are behavioral, medical and alternative interventions that have been effective provided they are implemented properly early in the diagnosis. ASD affects one in 110 children in the US. Lifetime cost per patient to the public system is estimated at \$3.5 million. 2010 cost to the US was approximately \$90 billion.

The market for objective diagnostic/screening tools is significant. We are currently working with a leading researcher from Children's Hospital in Boston that is developing an EEG-based technique to provide risk assessment of infants for developing Autism Spectrum Disorders. This noninvasive, objective screening tool could detect specific psychiatric biomarkers based on EEG analysis.

Objective diagnostic/screening tools such as EEG are desperately needed to better categorize patients with Autism Spectrum Disorders. Variability in behavioral diagnosis is significant and as a result many children are misdiagnosed or not diagnosed at all. Where timely behavioral intervention is critical to positive patient outcomes, it is crucial to give physicians and caregivers quality objective measures to better treat their patients.

We are currently looking for seed investment/development partners to further clinical studies with this technology, establish proof of concept and make commercially available.

Please contact us for more detailed information.

617 444 8780

kryan@geneousbiomedical.com